Meropenem decreases serum level of valproic acid

Pediatric Neurology

Volumn 31, Issue 3, 2004, Pages 232-234

  Nacarkucuk, Ergun ^a,c   Saglam, Halil ^b   Okan, Mehmet ^a  

^a Division of Pediatric Neurology

^b ULUDAG UNIVERSITY   (Turkey)

^c Dept Neurol Div Child N   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; MEROPENEM; TOBRAMYCIN; VALPROIC ACID; VANCOMYCIN;

ADOLESCENT; ARTICLE; CASE REPORT; CEREBRAL PALSY; CHILD; CLINICAL FEATURE; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG GLUCURONIDATION; DRUG WITHDRAWAL; FEMALE; HOSPITAL ADMISSION; HUMAN; MALE; PATIENT MONITORING; PNEUMONIA; PRIORITY JOURNAL; SEIZURE; SEIZURE SUSCEPTIBILITY;

ADOLESCENT; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; MALE; THIENAMYCINS; VALPROIC ACID;

EID: 4544265039     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2004.03.014     Document Type: Article

References (13)

1. B.J.G. De Turck, M.W. Diltoer, and P.J. Cornelis Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and mikacin. J Antimicrob Chemother 42 1998 563 564
2. S.R. Norrby, K.M. Gildon Safety profile of meropenem A review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis 31 1999 3 10
3. S.R. Norrby, P.A. Newell, K.L. Faulkner, W. Lesky Safety profile of meropenem International clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 36 Suppl. A 1995 207 223
4. G. Zaccara, A. Messori, F. Moroni Clinical pharmacokinetics of valproic acid Clin Pharmacokinet 15 1988 367 389
5. K. Nagai, T. Shimizu, M. Togo Decrease in serum levels of valproic acid during treatment with a new carbapenem, anipenem/betamipron J Antimicrob Chemother 39 1995 295 296
6. R. Riva, F. Albani, M. Contin Pharmacokinetic.interactions between antiepileptic drugs Clin Pharmacokinet 31 1996 470 493
7. K. Yokogawa, S. Iwashita, A. Kubota Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits Pharm Res 18 2001 1320 1326
8. F. Ichimura, Y. Deguchi, K. Yokogawa, T. Yamana Physiologically.based pharmacokinetics of valproic acid in rabbits Int J Pharm 27 1985 45 60
9. M.I. Mataringa, T.W. May, B. Rambeck Does.lamotrigine influence valproate concentrations? Ther.Drug Monit 24 2002 631 636
10. A.K. Birnbaum, R.L. Kriel, J.C. Cloyd Pharmacokinetics.in infancy, childhood, and adolescence E. Wyllie The.treatment of epilepsy, principles and practice 2001 Lippincott Williams Wilkins Philadelphia 741 757
11. S. Kojima, M. Nadai, K. Kitaichi, L. Wang, T. Nabeshima, T. Hasegawa Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats Antimicrob Agents Chemother 42 1998 3136 3140
12. N. Yamamura, K. Imura, H. Naganuma, K. Nishimura Panipenem, a carbapenem antibiotic, enhances the glucoronidation of intravenously administered valproic acid in rats Drug Metab Dispos 27 1999 724 730
13. N. Hobara, H. Kameya, N. Hokama, S. Oshiro Altered.pharmacokinetics of sodium valproate by simultaneous administration.with imipenem/cilastatin sodium Jpn Hosp Pharm 24 1998 464 472